KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Prepaid Assets: 2013-2025

Historic Prepaid Assets for Xenon Pharmaceuticals (XENE) over the last 11 years, with Sep 2025 value amounting to $17.1 million.

  • Xenon Pharmaceuticals' Prepaid Assets rose 264.00% to $17.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.1 million, marking a year-over-year increase of 264.00%. This contributed to the annual value of $6.9 million for FY2024, which is 14.72% up from last year.
  • Xenon Pharmaceuticals' Prepaid Assets amounted to $17.1 million in Q3 2025, which was up 46.92% from $11.6 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' Prepaid Assets' 5-year high stood at $17.1 million during Q3 2025, with a 5-year trough of $2.9 million in Q2 2023.
  • Its 3-year average for Prepaid Assets is $7.0 million, with a median of $6.0 million in 2023.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Prepaid Assets slumped by 58.53% in 2023, and later surged by 264.00% in 2025.
  • Xenon Pharmaceuticals' Prepaid Assets (Quarterly) stood at $4.5 million in 2021, then soared by 61.24% to $7.2 million in 2022, then declined by 16.87% to $6.0 million in 2023, then climbed by 14.72% to $6.9 million in 2024, then surged by 264.00% to $17.1 million in 2025.
  • Its Prepaid Assets was $17.1 million in Q3 2025, compared to $11.6 million in Q2 2025 and $7.3 million in Q1 2025.